company background image
KRRO logo

Korro Bio NasdaqCM:KRRO Stock Report

Last Price

US$41.60

Market Cap

US$394.1m

7D

-10.3%

1Y

n/a

Updated

14 Jun, 2024

Data

Company Financials +

KRRO Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States.

KRRO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Korro Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Korro Bio
Historical stock prices
Current Share PriceUS$41.60
52 Week HighUS$97.91
52 Week LowUS$14.00
Beta0
1 Month Change-21.17%
3 Month Change-32.38%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO168.73%

Recent News & Updates

We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth

Mar 30
We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth

Recent updates

We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth

Mar 30
We Think Korro Bio (NASDAQ:KRRO) Can Afford To Drive Business Growth

Shareholder Returns

KRROUS BiotechsUS Market
7D-10.3%0.02%1.2%
1Yn/a6.7%20.6%

Return vs Industry: Insufficient data to determine how KRRO performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how KRRO performed against the US Market.

Price Volatility

Is KRRO's price volatile compared to industry and market?
KRRO volatility
KRRO Average Weekly Movement11.7%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: KRRO's share price has been volatile over the past 3 months.

Volatility Over Time: KRRO's weekly volatility has decreased from 21% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201894Ram Aiyarwww.korrobio.com

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates.

Korro Bio, Inc. Fundamentals Summary

How do Korro Bio's earnings and revenue compare to its market cap?
KRRO fundamental statistics
Market capUS$394.10m
Earnings (TTM)-US$81.12m
Revenue (TTM)n/a

0.0x

P/S Ratio

-4.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KRRO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$81.12m
Earnings-US$81.12m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-8.75
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did KRRO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.